1
|
Balcázar-Valencia CM, García-Ramos AF, Osorio-Toro LM, Ordoñez-Guzmán YA, Buitrago-Gómez N, Cabarcas-López WF, Vizcaino-Guerrero CJ, Daza-Arana JE, Ramírez-Rincón A, Restrepo-Erazo K. Semaglutide Effects on Metabolic Outcomes in Diabetes Mellitus Patients - Real World Study. Diabetes Metab Syndr Obes 2024; 17:1667-1673. [PMID: 38616987 PMCID: PMC11016261 DOI: 10.2147/dmso.s443115] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/21/2023] [Accepted: 01/11/2024] [Indexed: 04/16/2024] Open
Abstract
Purpose Diabetes is a public health problem that requires strategies to impact glycemic control and reduce the risk of long-term medical complications. Pharmacological management is a necessary treatment for this disease. Therefore, semaglutide is an essential tool to achieve the treatment targets. The present study aimed to evaluate the semaglutide effects on a cohort with type 2 diabetes mellitus (T2DM) in Colombia. Materials and Methods The cohort included 49 patients with T2DM that have been treated in a specialized care center. Their glycemic outcomes, weight, renal function, and adverse events were evaluated through a 3-, 6- and 12-month follow-up. Results Significant differences were observed in the outcome evaluation: reduction of glycated hemoglobin levels (MD -2.74 CI -1.95 to -3.52 in 6 months), fasting plasma glucose levels, body weight (MD -7.11 CI -5.97 to -8.24), and the albumin-to-creatinine ratio. The results were maintained throughout the treatment period. The adverse event rate was 16.3%, predominating gastrointestinal events. Conclusion This real-world evidence shows the efficacy of semaglutide in achieving treatment goals in patients with T2DM.
Collapse
Affiliation(s)
| | - Andrés Felipe García-Ramos
- Specialization in Internal Medicine, Faculty of Health, Universidad Santiago de Cali, Santiago de Cali, Colombia
- Research and Education Department, Clínica de Occidente S.A., Santiago de Cali, Colombia
- Specialization in Endocrinology, Faculty of Health Sciences, Universidad Pontificia Bolivariana, Medellín, Colombia
- Specialization in Internal Medicine, Faculty of Health, Universidad del Valle, Santiago de Cali, Colombia
| | - Luis Miguel Osorio-Toro
- Specialization in Internal Medicine, Faculty of Health, Universidad Santiago de Cali, Santiago de Cali, Colombia
- Research and Education Department, Clínica de Occidente S.A., Santiago de Cali, Colombia
- Genetics, Physiology and Metabolism Research Group (GEFIME), Faculty of Health Sciences, Universidad Santiago de Cali, Santiago de Cali, Colombia
| | | | - Nathalia Buitrago-Gómez
- Specialization in Endocrinology, Faculty of Health Sciences, Universidad Pontificia Bolivariana, Medellín, Colombia
| | | | | | - Jorge Enrique Daza-Arana
- Specialization in Internal Medicine, Faculty of Health, Universidad Santiago de Cali, Santiago de Cali, Colombia
- Health and Movement Research Group, Faculty of Health Sciences, Universidad Santiago de Cali, Santiago de Cali, Colombia
| | - Alex Ramírez-Rincón
- Specialization in Endocrinology, Faculty of Health Sciences, Universidad Pontificia Bolivariana, Medellín, Colombia
| | - Katherine Restrepo-Erazo
- Specialization in Internal Medicine, Faculty of Health, Universidad Santiago de Cali, Santiago de Cali, Colombia
- Specialization in Endocrinology, Faculty of Health, Universidad Nacional de Colombia, Bogotá D.C., Colombia
| |
Collapse
|